benzodiazepine structures clonazepam upper left alprazolam lower left prescription benzodiazepines clonazolam upper right etizolam lower right designer benzodiazepines benzodiazepine class drugs approved therapeutic use country analogues synthesized drug companies cases went clinical trials published results never made market name makes seem like chemists synthesizing drugs purpose part original research benzodiazepine class medications really seen innovation decades drug current problem online sources allow people purchase tablet capsule powder blotter form several online venues users talk experience drug creates best high medical staff need realize many drugs undetectable molecules show false positives standard toxicology testing largely due lack reference material drug users often told drug undetectable standard toxicology assessments drugs also listed standard prohibited substance therefore legal high fairly weak argument users overtly intoxicated sustain consequences intoxication check i looked list designer benzodiazepines clonazolam deschloroetizolam diclazepam estazolam etizolam flubromazepam flubromazolam flutazolam hydroxyphenazepam meclonazepam nifoxipam phenazepam pyrazolam compared recent posted list controlled substances dea one compounds estazolam listed current list dated may listed schedule iv drug i way knowing compounds considered list list deter illegal sale controlled substances designer designation generally means far less known drug terms safety cases toxicology lags behind exposures physicians treating intoxication withdrawal overdoses compounds uncertain treating patient collateral contacts patient may know drug lag time creates additional danger patient first time i searched clonazolam medline i impressed fact references medical literature including analysis reference listed designer benzodiazepines fact analysis also described complications intoxicated driving taking complications life threatening intoxication minimal online information available suggests high potency doses suggested range high potency benzodiazepines clinical applications result fda package inserts even reliable data agencies listed british national formulary bnf org despite lack clinical information application immediately obvious large quantities available purchase online sites described research chemical clinical applications also described human consumption label i familiar synthetic cannabinoids current problem long chemical precursors listed controlled substances anyone purchase purpose suggested prices quoted drug far street price diverted prescription benzodiazepines makes compounds ideal illegal trafficking searching etizolam medline resulted references clinical trials trials recent trials anxiety disorders based abstracts results sound equivocal ranging improvement weeks improvement striking feature trials dose etizolam mg bid indicating high potency benzodiazepine fact several studies done drug never approved suggests either lack sufficiently powered studies side effect obvious pharmaceutical company regulators cases drug also difficult use clinically several examples benzodiazepine class medications determined problematic use either banned point additional warning issued one disturbing trends recently number benzodiazepine compounds involved polypharmacy overdoses recent analysis overdoses cdc top compounds alprazolam diazepam prescription benzodiazepines cases overdoses involved concomitant drugs fatal opioid overdoses involve benzodiazepines due current problems analysis highly likely designer benzodiazepines involved overdose deaths detected compelling reason use designer benzodiazepines reading web sites promote use compounds ironic messages drugs used safely adequate research user internet prescription medications understood qualified safety approved fda prescribed qualified physician still completely unanticipated reactions approved medications generally tested addictive compounds reactions detected pharmacosurveillance much larger database case designer benzodiazepines approved prescribed highly potent drugs sold sources responsibility user anyone seeking get high context questioning value getting high george dawson md dfapa references pettersson bergstrand helander hansson beck detectability designer benzodiazepines cedia emit ii plus heia kims ii immunochemical screening assays drug test anal apr doi dta epub jul pubmed pmid iseth tuv ss karinen r blood concentrations new designer benzodiazepines forensic cases forensic sci nov doi forsciint epub sep pubmed pmid ukasik bocka sommerfeld k te yk zieli ska psuja panie ski p aba flubromazolam new life threatening designer benzodiazepine clin toxicol phila doi epub nov pubmed pmid savoldi f somenzini ecari etizolam versus placebo treatment ofpanic disorder agoraphobia double blind study curr med res opin pubmed pmid de candia mp di sciascio durbano f mencacci rubiera aguglia garavini bersani di sotto placidi cesana bm effects treatment etizolam mg bid cognitive performance week multicenter randomized double blind placebo controlled two treatment three period noninferiority crossover study patients anxiety disorder clin ther dec doi clinthera pubmed pmid